


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A pharmaceutical composition having antitumor activity with reduced side effect(s) comprising an effective amount of a known active substance having antitumor effect selected from the group consisting of pyrimidine derivatives or, optionally, a pharmaceutically acceptable acid addition salt thereof, and an effective amount of a hydroximic acid derivative of the formula I



wherein

R¹ represents a hydrogen atom or a C₁₋₅ alkyl group,

R² stands for a hydrogen atom, a C₁₋₅ alkyl group, a C₃₋₈ cycloalkyl group or a phenyl group optionally substituted by a hydroxy or a phenyl group, or

R¹ and R² together with the nitrogen atom they are attached to form a 5 to 8 membered ring optionally containing one or more further

nitrogen, oxygen or sulfur atom(s) and said ring can be condensed with another alicyclic or heterocyclic ring, ~~preferably a benzene, naphthalene, quinoline, isoquinoline, pyridine or pyrazoline ring,~~ furthermore optionally the nitrogen and/or sulfur heteroatom(s) are present in the form of an oxide or dioxide,


R³ means a hydrogen atom, a phenyl group, a naphthyl group or a pyridyl group wherein said groups can be substituted by one or more halo atom(s) or C₁₋₄ alkoxy group(s),

Y is a hydrogen atom, a hydroxy group, a C₁₋₂₄ alkoxy group optionally substituted by an amino group, a C₂₋₂₄ polyalkenyloxy group containing 1 to 6 double bond(s), a C₁₋₂₅ alkanoyl group, a C₃₋₉ alkenoyl group or a group of the formula R⁷-COO-

wherein R⁷ represents a C₂₋₃₀ polyalkenyl group containing 1 to 6 double bond(s),

X stands for a halo atom, an amino group, a C₁₋₄ alkoxy group or X forms with B an oxygen atom, or

X and Y together with the carbon atom they are attached to and the -NR-O-CH₂- group being between said carbon atoms form a ring of the formula a




wherein

Z represents an oxygen atom or a nitrogen atom,

R stands for a hydrogen atom or

R forms with B a chemical bond,

A is a C₁₋₄ alkylene group or a chemical bond or a group of the formula b



wherein

R⁴ represents a hydrogen atom, a C₁₋₅ alkyl group, a C₃₋₈ cycloalkyl group or a phenyl group optionally substituted by a halo atom, a C₁₋₄ alkoxy group or a C₁₋₅ alkyl group,

R⁵ stands for a hydrogen atom, a C₁₋₄ alkyl group or a phenyl group,

m has a value of 0, 1 or 2,

n has a value of 0, 1 or 2,

or a pharmaceutically acceptable acid addition salt thereof in admixture with one or more conventional carrier(s),

wherein the antitumor activity is against tumors sensitive to the combination.

Claim 2. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof as the hydroximic acid derivative of the formula I.

Claim 3. (Original) A pharmaceutical composition as claimed in claim 1, comprising fluorouracil or a pharmaceutically acceptable salt thereof as the active substance having antitumor activity.

Claims 4-5. (Canceled).

Claim 6. (Previously Presented) A method for reducing the side effect(s) in a patient requiring a treatment for a tumor comprising administering an effective amount of a known active substance having antitumor effect selected from the group consisting of pyrimidine derivatives or, optionally, a pharmaceutically acceptable acid addition salt thereof and an effective non-toxic amount of a hydroximic acid derivative of the formula I, wherein R^1 , R^2 , R^3 , A, X, B, R and Y are as defined in Claim 1, or a pharmaceutically acceptable acid addition salt

thereof to the patient, and wherein said tumor is sensitive to said active substance; and the administration of the hydroximic acid derivative or a pharmaceutically acceptable acid addition salt thereof reduces the side effects experienced by the patient requiring treatment for a tumor.

Claim 7. (Previously Presented) A method as claimed in claim 6, wherein said active substance is fluorouracil or a pharmaceutically acceptable salt thereof, and said hydroximic acid derivative is O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof.

Claims 8-9. (Canceled).

Claim 10. (Previously Presented) A method as claimed in claim 6, wherein said hydroximic acid derivative is O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof.

Claim 11. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising floxuridine or a

pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 12. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising idoxuridine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 13. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising doxifluiridine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 14. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising cytarabine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 15. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising gemcitabine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 16. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising ancitabine or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 17. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising carmofur or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 18. (Previously Presented) A pharmaceutical composition as claimed in claim 1, comprising tegafur or a pharmaceutically acceptable acid addition salt thereof as the active substance having antitumor activity.

Claim 19. (Previously Presented) A pharmaceutical composition having antitumor activity with reduced side effect(s) comprising an enhanced effective amount of fluorouracil or a pharmaceutically acceptable acid addition salt thereof and O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof, wherein

said antitumor activity is against tumors sensitive to said composition.

Claim 20. (New) The pharmaceutical composition according to claim 1, wherein said alicyclic or heterocyclic ring is selected from the group consisting of benzene, naphthalene, quinoline, isoquinoline, pyridine, and pyrazoline.